TRVI Trevi Therapeutics Inc
Price (delayed)
$6.28
Market cap
$607.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.47
Enterprise value
$574.1M
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation
Highlights
The equity has surged by 69% since the previous quarter and by 21% year-on-year
Trevi Therapeutics's debt has decreased by 23% YoY and by 7% from the previous quarter
Trevi Therapeutics's quick ratio has increased by 43% QoQ but it has decreased by 28% YoY
Trevi Therapeutics's net income has plunged by 65% YoY and by 8% from the previous quarter
The EPS has shrunk by 62% YoY and by 7% QoQ
Key stats
What are the main financial stats of TRVI
Market
Valuations
Earnings
Shares outstanding
96.68M
Market cap
$607.16M
Enterprise value
$574.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$51.52M
Net income
-$47.91M
EBIT
-$47.94M
EBITDA
-$47.79M
Free cash flow
-$38.29M
Per share
Balance sheet
Liquidity
EPS
-$0.47
EPS diluted
-$0.47
Free cash flow per share
-$0.38
Book value per share
$1.3
Revenue per share
$0
TBVPS
$1.09
Total assets
$110.9M
Total liabilities
$11.26M
Debt
$1.03M
Equity
$99.64M
Working capital
$98.92M
Debt to equity
0.01
Current ratio
10.41
Quick ratio
10.24
Net debt/EBITDA
0.69
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57.7%
Return on equity
-64.5%
Return on invested capital
-84%
Return on capital employed
-47.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRVI stock price
How has the Trevi Therapeutics stock price performed over time
Intraday
4.49%
1 week
-2.94%
1 month
38.94%
1 year
94.43%
YTD
52.43%
QTD
-0.16%
Financial performance
How have Trevi Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.52M
Net income
-$47.91M
Gross margin
N/A
Net margin
N/A
Trevi Therapeutics's net income has plunged by 65% YoY and by 8% from the previous quarter
The operating income has plunged by 52% YoY and by 7% from the previous quarter
Growth
What is Trevi Therapeutics's growth rate over time
Valuation
What is Trevi Therapeutics stock price valuation
P/E
N/A
P/B
4.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 62% YoY and by 7% QoQ
The P/B is 102% above the 5-year quarterly average of 2.3 and 36% above the last 4 quarters average of 3.4
The equity has surged by 69% since the previous quarter and by 21% year-on-year
Efficiency
How efficient is Trevi Therapeutics business performance
Trevi Therapeutics's return on invested capital has shrunk by 122% YoY
Trevi Therapeutics's return on equity has shrunk by 105% YoY
TRVI's ROA has plunged by 100% YoY
Dividends
What is TRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRVI.
Financial health
How did Trevi Therapeutics financials performed over time
The company's total liabilities has surged by 64% YoY and by 13% QoQ
The total assets has surged by 61% since the previous quarter and by 24% year-on-year
Trevi Therapeutics's debt is 99% less than its equity
The equity has surged by 69% since the previous quarter and by 21% year-on-year
TRVI's debt to equity has dropped by 50% since the previous quarter and by 50% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.